Market open
PDS Biotechnology/$PDSB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About PDS Biotechnology
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Ticker
$PDSB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
25
Website
PDSB Metrics
BasicAdvanced
$121M
Market cap
-
P/E ratio
-$1.21
EPS
1.89
Beta
-
Dividend rate
Price and volume
Market cap
$121M
Beta
1.89
52-week high
$6.85
52-week low
$2.53
Average daily volume
412K
Financial strength
Current ratio
3.838
Quick ratio
3.683
Long term debt to equity
44.969
Total debt to equity
78.849
Interest coverage (TTM)
-8.62%
Management effectiveness
Return on assets (TTM)
-39.95%
Return on equity (TTM)
-128.40%
Valuation
Price to book
3.9
Price to tangible book (TTM)
3.9
Price to free cash flow (TTM)
-3.191
Growth
Earnings per share change (TTM)
-24.69%
3-year earnings per share growth (CAGR)
31.31%
What the Analysts think about PDSB
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for PDS Biotechnology stock.
PDSB Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PDSB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PDSB News
AllArticlesVideos
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time
GlobeNewsWire·2 days ago
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
GlobeNewsWire·1 month ago
PDS Biotechnology: Continuing The Holding Pattern
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for PDS Biotechnology stock?
PDS Biotechnology (PDSB) has a market cap of $121M as of November 08, 2024.
What is the P/E ratio for PDS Biotechnology stock?
The price to earnings (P/E) ratio for PDS Biotechnology (PDSB) stock is 0 as of November 08, 2024.
Does PDS Biotechnology stock pay dividends?
No, PDS Biotechnology (PDSB) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next PDS Biotechnology dividend payment date?
PDS Biotechnology (PDSB) stock does not pay dividends to its shareholders.
What is the beta indicator for PDS Biotechnology?
PDS Biotechnology (PDSB) has a beta rating of 1.89. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.